Aditum Bio and Leads Biolabs join forces to fight autoimmune …
Nov 7, 2024 · The U.S. company Aditum Bio and Chinese company Leads Biolabs today announced that they have founded Oblenio Bio, a new company that will develop a potentially …
FDA removes clinical hold on Novavax’s COVID-19-influenza …
Nov 12, 2024 · The U.S. company Novavax announced yesterday that the FDA has removed the clinical hold placed on its COVID-19-influenza combination (CIC) vaccine and the stand-alone …
BridgeBio wins FDA Approval for cardiomyopathy treatment
Nov 26, 2024 · The exact prevalence of ATTR-CM is uncertain but is thought to be higher than previously thought. Estimates have increased from 5 in 100,000 people in 2004 to 35 per …
Amgen: Phase 2 results for GLP-1-GIP weight loss drug
Nov 28, 2024 · A number of different drugs, such as Novo Nordisk’s Ozempic, target either the GLP-1 or GIP receptor. Like Eli Lilly’s Mounjaro/Zepbound (tirzepatide), MariTide targets both …
Nucleus RadioPharma secures Series A investment from AstraZeneca
Jun 6, 2024 · Nucleus RadioPharma, a leading player in the development, manufacturing, and supply chain management of radiopharmaceuticals, has announced a significant milestone …
Ottimo Pharma emerges from stealth mode with promising cancer …
Oct 29, 2024 · UK-based private biotech company Ottimo Pharma has emerged from stealth mode after four years with the appointment of a strong leadership team.
EMA accepts Marketing Authorization Application for biosimilar to …
Nov 5, 2024 · The European Medicines Agency (EMA) has accepted Alvotech and Advanz Pharma’s marketing authorization application for AVT05, a biosimilar to Johnson & Johnson’s …
Phase 1 clinical trials using program APTN-101 to target …
Sep 10, 2024 · US biotech company Adaptin Bio has emerged from stealth with the announcement that the FDA has cleared an Investigational New Drug application (IND) for its …
Thermo Fisher - accelerating the shift towards precision medicine
Oct 22, 2024 · Thermo Fisher’s John Lesica discusses how mass spectrometry technology enables scientific breakthroughs in genomics and proteomics to provide valuable insights for …
BMS achieves FDA approval for schizophrenia drug Cobenfy
Oct 1, 2024 · Bristol Myers Squibb (BMS) acquired Karuna Therapeutics, the developer of KarXT, in a deal worth US $14.0 billion in equity value that completed earlier this year. The deal has …